Copenhagen, Denmark-based Egalet AS, a company focused on the development of therapeutics utilizing its proprietary erosion technology, has announced the signing of a long-term manufacturing agreement with SP Medical AS, a fellow Danish company that manufactures moulded plastics and coatings.
Under the terms of the deal, SP will produce sufficient clinical-grade quantities of Egalet products that are about to enter Phase III testing for hypertension and pain management and, if they gain regulatory approval, SP will also undertake commercial scale-up and manufacture. The firm noted that all manufacturing is subject to approval by Danish authorities and the US Food and Drug Administration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze